These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9155061)

  • 1. Elevated serum levels of S100 and survival in metastatic malignant melanoma.
    Buer J; Probst M; Franzke A; Duensing S; Haindl J; Volkenandt M; Wittke F; Hoffmann R; Ganser A; Atzpodien J
    Br J Cancer; 1997; 75(9):1373-6. PubMed ID: 9155061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
    Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
    Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum S100--a marker for disease monitoring in metastatic melanoma.
    Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
    Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
    Franzke A; Probst-Kepper M; Buer J; Duensing S; Hoffmann R; Wittke F; Volkenandt M; Ganser A; Atzpodien J
    Br J Cancer; 1998 Jul; 78(1):40-5. PubMed ID: 9662248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100 protein serum levels in cutaneous malignant melanoma.
    Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
    Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
    Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
    Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma.
    Bolander A; Agnarsdóttir M; Wagenius G; Strömberg S; Pontén F; Ekman S; Brattström D; Larsson A; Einarsson R; Ullenhag G; Hesselius P; Bergqvist M
    Melanoma Res; 2008 Dec; 18(6):412-9. PubMed ID: 19011512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
    Jury CS; McAllister EJ; MacKie RM
    Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Desch A; Gebhardt C; Utikal J; Schneider SW
    Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
    Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
    Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
    Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
    Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
    Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
    Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100 serum level: a tumour marker for metastatic melanoma.
    Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
    Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
    Schultz ES; Diepgen TL; Von Den Driesch P
    Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients.
    Smit LH; Korse CM; Hart AA; Bonfrer JM; Haanen JB; Kerst JM; Nieweg OE; de Gast GC
    Eur J Cancer; 2005 Feb; 41(3):386-92. PubMed ID: 15691637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.